home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 04/27/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn up 10% on completion of leronlimab application for HIV

CytoDyn ( OTCQB:CYDY +10.1% ) has completed the rolling submission of its U.S. marketing application seeking approval to use leronlimab, combined with highly active antiretroviral therapy (HAART), in treatment-experienced HIV patients, a Fast Track-tagged indication. More news on: Cyto...
CYDY - CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United States

VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today an...

CYDY - CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients

During the FDA’s review period, the Company will dedicate all resources to ensure availability of leronlimab for COVID-19 patients; Cancer programs continue with positive results VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“C...

CYDY - CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine

VANCOUVER, Washington, April 24, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
CYDY - Scientists Worldwide Feverishly Working to Develop New Drug and Vaccine Candidates for COVID-19 Crisis

April 23, 2020 Palm Beach, FL – April 23, 2020 – America’s biopharmaceutical companies have recently reiterated that they are committed to developing solutions to help diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus. I...

CYDY - CytoDyn: Timeline To COVID-19 Credibility

CytoDyn's ( CYDY ) most recent (4/17/20) Wall Street Live, " Next Superstock " promo, was worth the time invested for those who are trying to make sense of a CytoDyn investment. It was a new format with CytoDyn's hard-working CEO Nader Pourhassan [NP] moderating a series of questions for CytoD...

CYDY - CytoDyn's Leronlimab In COVID-19: Debunking The Short Thesis

Introduction CytoDyn ( CYDY ) shares have been on a tear over the last few months, moving from just under $0.30 in December to an intraday high of ~$3.50 merely months later. From signing a commercialization deal with Vyera to launching a promising basket trial in over 20 different metasta...
CYDY - CytoDyn's Trial Starts, And Other News: The Good, Bad And Ugly Of Biopharma

CytoDyn Treats First Patient In Leronlimab Trial CytoDyn Inc. ( CYDY ) reported that it has treated the first patient in its Phase 2 basket trial for 22 solid cancer tumors. The trial deals with a wide range of cancers and tumors such as throat, stomach, lungs, bladder, and uterine among o...

CYDY - CytoDyn Appoints Samir Patel, M.D., to its Board of Directors

VANCOUVER, Washington, April 20, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...

CYDY - CytoDyn to Present at Wall Street Reporter's "NEXT SUPER STOCK" Livestream Event on April 17, 2020 at 12:30 pm ET / 9:30 am PT

VANCOUVER, Washington, April 16, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announce...
Previous 10 Next 10